Sigrun Ådnegard Skarstad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sigrun Ådnegard Skarstad has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Eivind Øygard Fosse
Department of Cardiology, University Hospital of North Norway, Tromsø, Norway
1 shared publication - Halvard Grendstad
Department of Physical Performance Norwegian School of Sport Sciences Oslo Norway
1 shared publication Jan Erik Nordrehaug
Department of Clinical Science, University of Bergen, Bergen, Norway
1 shared publicationJan Mannsverk
Department of Cardiology, University Hospital of North Norway, Tromsø, Norway
1 shared publication- Jostein Hallén
Department of Physical Performance Norwegian School of Sport Sciences Oslo Norway
1 shared publication Kaare Harald Bønaa
Clinic of Cardiology, St. Olavs University Hospital, Trondheim, Norway
1 shared publication
Latest Publications
- 18 January 2025
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 35 (1) , e70016
A Prospective Study on Maximal Oxygen Uptake and Cardiovascular Functions in 12‐Year‐Old Endurance Athletes and Their Non‐Endurance‐Trained Peers
The maximal oxygen uptake (V̇O2max) is typically higher in endurance‐trained adolescents than in non‐endurance‐trained peers. However, the specific mechanisms contributing to this remain unclear, as well as the impact of training during this developmental stage. This study aims to compare V̇O2max and cardiovascular functions between 12‐year‐old endurance athletes and non‐endurance‐trained over a 14‐month period. Anthropometrics, V̇O2max, hemoglobin mass (Hbmass), blood volume (BV), and left‐ventricular morphology were assessed four times over the 14 months in a group of young cross‐country skiers (END, n = 42, age: 12.4 ± 0.5, girls: n = 27) and a group of controls (CON, n = 26, age: 12.3 ± 0.3, girls: n = 15). Throughout the 14‐month follow‐up, END did more weekly training than CON (7.0 ± 2.3 vs. 2.5 ± 2.4 h, p < 0.001), with only END conducting endurance training. END had ~18% higher V̇O2max relative to fat‐free mass (FFM) than CON (p < 0.001). Stroke volume (SV) and left ventricular end‐diastolic volume (LV EDV) relative to FFM were also higher for END than CON (p < 0.001 and 0.004), while no significant differences were found for Hbmass and BV. No significant interaction was seen for group and time for V̇O2max (p = 0.352–0.767) or any cardiovascular parameters (p = 0.131–0.956) in absolute measures or relative to FFM. In conclusion, the END group exhibited higher V̇O2max, LV EDV, and SV compared to the CON group, with no significant difference in BV and Hbmass. Despite substantial differences in training volume, the progression of these variables over the 14‐month period was similar in both groups.
- 18 January 2025
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 35 (1) , e70016
A Prospective Study on Maximal Oxygen Uptake and Cardiovascular Functions in 12‐Year‐Old Endurance Athletes and Their Non‐Endurance‐Trained Peers
The maximal oxygen uptake (V̇O2max) is typically higher in endurance‐trained adolescents than in non‐endurance‐trained peers. However, the specific mechanisms contributing to this remain unclear, as well as the impact of training during this developmental stage. This study aims to compare V̇O2max and cardiovascular functions between 12‐year‐old endurance athletes and non‐endurance‐trained over a 14‐month period. Anthropometrics, V̇O2max, hemoglobin mass (Hbmass), blood volume (BV), and left‐ventricular morphology were assessed four times over the 14 months in a group of young cross‐country skiers (END, n = 42, age: 12.4 ± 0.5, girls: n = 27) and a group of controls (CON, n = 26, age: 12.3 ± 0.3, girls: n = 15). Throughout the 14‐month follow‐up, END did more weekly training than CON (7.0 ± 2.3 vs. 2.5 ± 2.4 h, p < 0.001), with only END conducting endurance training. END had ~18% higher V̇O2max relative to fat‐free mass (FFM) than CON (p < 0.001). Stroke volume (SV) and left ventricular end‐diastolic volume (LV EDV) relative to FFM were also higher for END than CON (p < 0.001 and 0.004), while no significant differences were found for Hbmass and BV. No significant interaction was seen for group and time for V̇O2max (p = 0.352–0.767) or any cardiovascular parameters (p = 0.131–0.956) in absolute measures or relative to FFM. In conclusion, the END group exhibited higher V̇O2max, LV EDV, and SV compared to the CON group, with no significant difference in BV and Hbmass. Despite substantial differences in training volume, the progression of these variables over the 14‐month period was similar in both groups.
- 8 December 2021
- Published by S. Karger AG in Cardiology
- Vol. 147 (1) , 14-22
Drug-Eluting versus Bare-Metal Stents in Saphenous Vein Grafts Compared to Native Coronary Vessels: The Norwegian Coronary Stent Trial Study
Background: Drug-eluting stents (DES) reduce target lesion revascularization (TLR) with no effect on mortality or myocardial infarction (MI) compared to bare-metal stents (BMS) in native vessels. Randomized stent studies in saphenous vein grafts (SVG) are few and the reported effects are ambiguous. The Norwegian Coronary Stent Trial study is the first to randomize lesions to percutaneous coronary intervention in native vessels and SVG. Aims: The aim of this study was to compare the rate of mortality, MI, and TLR across stent and vessel types. Methods: In this substudy, 6,087 patients with a single lesion in native vessels and 164 in SVG were followed for 5 years. Results: MI was more frequent in SVG (subdistributional hazard ratio [SHR] 4.95 (3.75–6.54, p < 0.001), but not affected by stent type. In the first 500 days, DES reduced TLR in native vessels (SHR 0.21 (0.15–0.30) p < 0.001) and SVG (SHR 0.18 (0.04–0.80) p = 0.02). Thereafter, DES and BMS were equivalent in native vessels, but DES had a higher TLR rate than BMS in SVG (SHR 3.31 (1.23–8.94) p = 0.02). After 5 years, the TLR rate was still significantly lower for DES in native vessels (3.2% vs. 7.8%, p < 0.001) but not in SVG (21.4% vs. 18. 4%). Conclusion: In SVG, no difference in TLR between DES and BMS was observed after 5 years in contrast to persistent benefit in native vessels. The high rate of TLR and MI in SVG makes treatment of native vessels a preference whenever feasible and better treatment options for SVG are warranted.
- 8 December 2021
- Published by S. Karger AG in Cardiology
- Vol. 147 (1) , 14-22
Drug-Eluting versus Bare-Metal Stents in Saphenous Vein Grafts Compared to Native Coronary Vessels: The Norwegian Coronary Stent Trial Study
Background: Drug-eluting stents (DES) reduce target lesion revascularization (TLR) with no effect on mortality or myocardial infarction (MI) compared to bare-metal stents (BMS) in native vessels. Randomized stent studies in saphenous vein grafts (SVG) are few and the reported effects are ambiguous. The Norwegian Coronary Stent Trial study is the first to randomize lesions to percutaneous coronary intervention in native vessels and SVG. Aims: The aim of this study was to compare the rate of mortality, MI, and TLR across stent and vessel types. Methods: In this substudy, 6,087 patients with a single lesion in native vessels and 164 in SVG were followed for 5 years. Results: MI was more frequent in SVG (subdistributional hazard ratio [SHR] 4.95 (3.75–6.54, p < 0.001), but not affected by stent type. In the first 500 days, DES reduced TLR in native vessels (SHR 0.21 (0.15–0.30) p < 0.001) and SVG (SHR 0.18 (0.04–0.80) p = 0.02). Thereafter, DES and BMS were equivalent in native vessels, but DES had a higher TLR rate than BMS in SVG (SHR 3.31 (1.23–8.94) p = 0.02). After 5 years, the TLR rate was still significantly lower for DES in native vessels (3.2% vs. 7.8%, p < 0.001) but not in SVG (21.4% vs. 18. 4%). Conclusion: In SVG, no difference in TLR between DES and BMS was observed after 5 years in contrast to persistent benefit in native vessels. The high rate of TLR and MI in SVG makes treatment of native vessels a preference whenever feasible and better treatment options for SVG are warranted.